	US 12,227,766 B2
	Cell-derived particles presenting heterologous CD24 and use thereof in therapy
Nadir Arber, Tel-Aviv (IL); and Shiran Shapira, Petach-Tikva (IL)
Assigned to Ichilov Tech Ltd., Tel-Avivv (IL)
Filed by Ichilov Tech Ltd., Tel-Aviv (IL)
Filed on Jul. 20, 2023, as Appl. No. 18/224,131.
Application 18/224,131 is a division of application No. 17/327,719, filed on May 23, 2021, abandoned.
Application 17/327,719 is a continuation in part of application No. PCT/IL2021/050432, filed on Apr. 15, 2021.
Application PCT/IL2021/050432 is a continuation in part of application No. 17/186,039, filed on Feb. 26, 2021, abandoned.
Claims priority of provisional application 63/010,830, filed on Apr. 16, 2020.
Prior Publication US 2024/0002810 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/705 (2006.01); C07K 14/71 (2006.01); C12N 5/00 (2006.01); C12N 5/071 (2010.01); C12N 5/077 (2010.01)

CPC C12N 5/0686 (2013.01) [C07K 14/71 (2013.01); C12N 5/0656 (2013.01); C12N 2500/90 (2013.01); C12N 2501/33 (2013.01); C12N 2501/599 (2013.01); C12N 2501/998 (2013.01)]

14 Claims

1. A method of treating a subject having a disease consisting of a coronavirus infection, the method comprising:

(a) isolating exosomes from a biological sample comprising cells genetically modified to present CD24 so as to obtain a preparation of the exosomes substantially devoid of intact cells; and

(b) administering to the subject via inhalation a therapeutically effective amount of the preparation of the exosomes,

thereby treating the coronavirus infection in the subject.